PolyPid Ltd. (Nasdaq: PYPD) has unveiled a breakthrough long-acting GLP-1 receptor agonist delivery platform that could revolutionize diabetes and weight management treatment by providing therapeutic drug levels for approximately 60 days with a single subcutaneous injection. The Israeli late-stage biopharma company announced this development on July 15, 2025, positioning itself to capture a significant share of the GLP-1 market projected to reach $100 billion by 2030.
Extended Release Technology Addresses Current Limitations
The new platform represents a substantial advancement over current GLP-1 therapies, which require weekly injections. PolyPid's system releases GLP-1 in a linear fashion, overcoming the burst release phenomenon associated with existing weekly delivery molecules. This controlled release mechanism aims to provide patients with consistent therapeutic levels of GLP-1 receptor agonists over an extended period.
"This recent discovery represents a potential paradigm shift in GLP-1 therapy delivery that could transform patient care in the rapidly expanding diabetes and weight management markets," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "By harnessing our proprietary prolonged-release technology, we aim to provide patients with consistent, therapeutic levels of GLP-1 for approximately 60 days with a single administration, potentially eliminating the need for weekly injections."
PLEX Technology Platform Demonstrates Clinical Validation
The delivery system utilizes PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which consists of a sophisticated polymer-lipid based matrix that creates a protected drug reservoir. This unique matrix architecture enables controlled and continuous drug delivery over prolonged periods ranging from weeks to months in a single application.
The technology has demonstrated clinical validation across over 1,000 patients, including participants in two Phase 3 trials, with no major safety concerns reported. This extensive clinical experience provides a foundation for the GLP-1 platform's development and potential regulatory pathway.
Market Expansion and Portfolio Diversification
The GLP-1 delivery platform expands PolyPid's product portfolio beyond its recently successful Phase 3 D-PLEX100 program, demonstrating the versatility of the company's proprietary drug delivery platforms across multiple major therapeutic areas. D-PLEX100, designed for the prevention of abdominal colorectal surgical site infections, is expected to have its New Drug Application (NDA) submitted in early 2026.
According to market projections cited by PolyPid, Goldman Sachs estimates the diabetes and weight loss market could reach $100 billion by 2030, driven primarily by GLP-1 therapies. J.P. Morgan Research forecasts that the GLP-1 market will exceed $100 billion by 2030, driven equally by diabetes and obesity usage.
Addressing Medication Adherence Challenges
The extended-release platform specifically targets medication adherence challenges in chronic disease management. Akselbrad emphasized that the technology "potentially marks a significant advancement in improving medication adherence and patient outcomes, addressing a critical gap in the treatment of obesity and type 2 diabetes chronic diseases."
The company's PLEX technology pairs with Active Pharmaceutical Ingredients (APIs) to enable precise delivery of drugs at optimal release rates. Beyond the GLP-1 platform, PolyPid is also developing OncoPLEX for solid tumor treatment, beginning with glioblastoma, currently in preclinical stages.
